BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8194022)

  • 1. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
    Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
    Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
    Reese DM; Corry M; Small EJ
    Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
    Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte PF
    Cancer; 1993 Jul; 72(2):564-8. PubMed ID: 8319188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
    Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
    Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
    Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
    J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
    Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
    Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
    von Roemeling R; Hrushesky WJ
    J Clin Oncol; 1989 Nov; 7(11):1710-9. PubMed ID: 2530318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
    Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
    Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
    Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
    Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
    Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
    Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
    Hrushesky WJ; Von Roemeling R; Fraley EE; Rabatin JT
    Semin Surg Oncol; 1988; 4(2):110-5. PubMed ID: 2969133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
    Trump DL; Ravdin PM; Borden EC; Magers CF; Whisnant JK
    J Biol Response Mod; 1990 Feb; 9(1):108-11. PubMed ID: 2319258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
    Liu JH; Yang MH; Fan FS; Yen CC; Wang WS; Chang YH; Chen KK; Chen PM
    Urology; 2001 Apr; 57(4):650-4. PubMed ID: 11306370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
    Mickisch GH; Noordzij MA; vd Gaast A; Gebreamlack P; Köhrmann KU; Mogler-Drautz E; Kupper H; Schröder FH
    J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R11-6. PubMed ID: 8698736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.